Memantine for Agitation in Dementia (MAGD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00371059
Recruitment Status : Unknown
Verified May 2008 by East Kent Hospitals University NHS Foundation Trust.
Recruitment status was:  Recruiting
First Posted : September 1, 2006
Last Update Posted : May 9, 2008
University of Oxford
Institute of Psychiatry, London
University of London
University College, London
Indiana University School of Medicine
Information provided by:
East Kent Hospitals University NHS Foundation Trust

Brief Summary:
We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks

Condition or disease Intervention/treatment Phase
Dementia Drug: Memantine Drug: Placebo Phase 4

Detailed Description:
Agitation is a cause of morbidity and mortality in Alzheimer's due to distress and use of medication with side effects. Memantine has beed shown to be associated with less agitation and a recent study by forrest pharmaceuticals failed to recruit. We will perform a 12 week rct in 164 patients to test this hypothesis in a locality with no competing studies and in a clinical setting where the drug is not often used. We will compare with placebo and also use a rescue protocol derived from international best practice.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 164 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia
Study Start Date : September 2007
Estimated Primary Completion Date : June 2009
Estimated Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia

Intervention Details:
  • Drug: Memantine
    Memantine 10mg BD
  • Drug: Placebo
    Placebo 10 mgs BD

Primary Outcome Measures :
  1. Cohen-Mansfield [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Neuropsychiatric Inventory 6+12 weeks [ Time Frame: 2 weeks ]
  2. Clinical Global Impression 6+ 12 weeks [ Time Frame: 2 weeks ]
  3. Severe Impairment Battery 6+12 weeks [ Time Frame: 2 weeks ]
  4. Quality of Life 6+12 weeks [ Time Frame: 2 weeks ]
  5. Co-meds [ Time Frame: 2 weeks ]
  6. Incidents of agitation [ Time Frame: 2 weeks ]
  7. Use of rescue protocol [ Time Frame: 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Residential/Inpatients at recruitment to the study with a history of at least 2 weeks behavioural disturbance.
  2. Alzheimer's Disease only as per McKhann Criteria + Hachinski Score<=4.
  3. Moderately severe to severe Alzheimer's Disease (baseline MMSE </=19).
  4. Clinically significant agitation that requires treatment.
  5. Severity of agitation defined by Cohen Mansfield agitation inventory (CMAI) > /=45.
  6. Age >/= 55.

Exclusion Criteria:

  1. Memantine usage in the 4 weeks prior to the start of the study.
  2. On Cholinesterase inhibitor for less than 3 months and not on a stable dose.
  3. Anti-psychotic, anti-epileptic, antidepressant, benzodiazepine, lithium or hypnotic dosage alteration in the 2 weeks prior to the start of the study.
  4. Antiparkinsonian medication.
  5. Hypersensitivity to memantine or any of the excipients in the formulation.
  6. Severe renal impairment.
  7. Epilepsy, history of convulsions or seizure, or receiving any anti-epileptic treatment.
  8. Concomitant usage of N-methyl-D-aspartate (NMDA) antagonists such as amantadine, ketamine or dextromethorphan.
  9. Recent myocardial infarction, uncompensated congestive heart failure and uncontrolled hypertension.
  10. Severe, unstable or poorly controlled medical illness.
  11. Any disability that may interfere with the patient completing the study procedure.
  12. Active malignancy.
  13. Delirium, pain or any medical illness as a clear cause of agitation.
  14. Any important drug interactions: Prohibited during study and in the 14 days preceding enrollment/inclusion are: Analgesic dextromethorphan, Dopaminergics- amantadine, Warfarin due to theoretical INR prolongation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00371059

Contact: CHRIS FOX, MBBSBscMsc 44-130-322-8836
Contact: ADRIAN TRELOAR, MB BS Bsc 44-132-262-5700

United Kingdom
Oxleas Nhs Foundation Trust Recruiting
Dartford, Kent, United Kingdom, DA2 7WG
Kent and Medway NHS and Social Care Partnership Trust Recruiting
Folkestone, Kent, United Kingdom, ct20 1jy
Sub-Investigator: MONICA CRUGEL, MRCPSYCH         
Sponsors and Collaborators
East Kent Hospitals University NHS Foundation Trust
University of Oxford
Institute of Psychiatry, London
University of London
University College, London
Indiana University School of Medicine

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: DR ART ATIONU, EAST KENT HOSPITALS TRUST Identifier: NCT00371059     History of Changes
Other Study ID Numbers: 2005-005087-93
ISRCTN 24953404
First Posted: September 1, 2006    Key Record Dates
Last Update Posted: May 9, 2008
Last Verified: May 2008

Keywords provided by East Kent Hospitals University NHS Foundation Trust:

Additional relevant MeSH terms:
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents